ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

RXR-alpha Variant-targeting Agent NM6603

Its studies are mostly in Neoplasms, led by NucMito Pharmaceuticals.

Furthest: phase 1, since Sep 5, 20232 company-led studies, 1 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
NucMito Pharmaceuticals21 open or runningphase 1since Sep 5, 2023Sep 5, 2023Nov 2026phase 1 · NCT07292038

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 5, 2023First study: phase 1 study in NeoplasmsFirst studyNCT06046066 · 17 enrolled · United States
  2. Nov 17, 2025Phase 1 study in NeoplasmsNCT07292038 · 30 planned · China

Ahead

  1. Nov 2026Primary completion: phase 1 study in NeoplasmsNCT07292038

TargetBeta

RXRA →read by rule
“An orally bioavailable small molecule agent that targets retinoid X receptor alpha (RXR-alpha; RXRA) variant, ”NCIt, by rule

Other programs on RXRA

ProgramCompanyFurthest phaseStudies
AGN 194204ruleio-therapeuticsphase 25

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07292038Neoplasms · China1RecruitingNov 202630
NCT06046066Neoplasms · United States1TerminatedApr 25, 202517

How it is read

Names in the registry

  • “NM6603”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.